{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:28:30Z","timestamp":1790818110522,"version":"4.1.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ajpc.2025.100945","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T16:25:09Z","timestamp":1739550309000},"page":"100945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6452-188X","authenticated-orcid":false,"given":"Victoria","family":"Clair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis M.","family":"Zirille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ajpc.2025.100945_bib0001","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"39","key":"10.1016\/j.ajpc.2025.100945_bib0002","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0003","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.ajpc.2025.100945_bib0004","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2022.09.021","article-title":"Equivalent impact of elevated lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic cardiovascular disease","volume":"80","author":"Hedegaard","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.1016\/j.ajpc.2025.100945_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"10.1016\/j.ajpc.2025.100945_bib0006","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0007","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0008","unstructured":"Alebna PL, Mehta A. An update on lipoprotein(a): the latest on testing, treatment, and guideline recommendations. American College of Cardiology. Accessed June 17, 2024. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2023\/09\/19\/10\/54\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2023%2f09%2f19%2f10%2f54%2fAn-Update-on-Lipoprotein-a."},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lipoprotein(a) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017470","article-title":"Lipoprotein(a) and coronary artery disease risk without a Family history of heart disease","volume":"10","author":"Finneran","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0012","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.3390\/ijms24065927","article-title":"A systematic review on the risk modulators of myocardial infarction in the \u201cyoung\u201d\u2014Implications of lipoprotein (a)","volume":"24","author":"St\u0103tescu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.ajpc.2025.100945_bib0013","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","article-title":"Lipoprotein(a) and risks of peripheral artery disease, abdominal aortic aneurysm, and major adverse limb events","volume":"82","author":"Thomas","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2025.100945_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody\u2013based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100945_bib0015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"21","key":"10.1016\/j.ajpc.2025.100945_bib0016","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): A randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2025.100945_bib0017","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","author":"Koschinsky","year":"2019","journal-title":"Clin Pract"},{"key":"10.1016\/j.ajpc.2025.100945_bib0018","doi-asserted-by":"crossref","first-page":"S534","DOI":"10.1016\/j.hlc.2024.06.895","article-title":"Review of current clinical strategies of managing patients with elevated lipoprotein(a): cost-effectiveness of lp(a) testing and patient awareness of lifestyle changes through public health policy in absence of a targeted therapy","volume":"33","author":"Adams","year":"2024","journal-title":"Heart Lung Circ"},{"issue":"16","key":"10.1016\/j.ajpc.2025.100945_bib0019","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2025.100945_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100651","article-title":"High lipoprotein(a): actionable strategies for risk assessment and mitigation","volume":"18","author":"Reyes-Soffer","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0021","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MOL.0000000000000950","article-title":"Strategies for management of patients with elevated lipoprotein(a)","volume":"35","author":"Ellberg","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0022","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100945_bib0023","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033562","article-title":"Aspirin and cardiovascular risk in individuals with elevated lipoprotein(a): the multi-ethnic study of atherosclerosis","volume":"13","author":"Bhatia","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100945_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100675","article-title":"Lipoprotein(a) and benefit of antiplatelet therapy","volume":"2","author":"Patel","year":"2023","journal-title":"JACC Adv"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jca.21525","article-title":"Case report of male child with elevated lipoprotein (a) leading to acute ischemic stroke","volume":"32","author":"Moriarty","year":"2017","journal-title":"J Clin Apheresis"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0028","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11883-023-01102-5","article-title":"Lipoprotein (a): does it play a role in pediatric ischemic stroke and thrombosis?","volume":"25","author":"Torres","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"8","key":"10.1016\/j.ajpc.2025.100945_bib0029","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2018.211433","article-title":"Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population","volume":"104","author":"deVeber","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ajpc.2025.100945_bib0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"De Boer","year":"2022","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCULATIONAHA.122.062592","article-title":"The value of measuring lipoprotein(a) in children","volume":"147","author":"Khoury","year":"2023","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.ajpc.2025.100945_bib0033","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1056\/NEJM199806043382302","article-title":"Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. the bogalusa heart study","volume":"338","author":"Berenson","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0034","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1542\/peds.2013-4096","article-title":"Committee on practice and ambulatory medicine, bright futures periodicity schedule workgroup. 2014 recommendations for pediatric preventive health care","volume":"133","year":"2014","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0035","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3390\/biomedicines11061661","article-title":"Evidence and uncertainties on lipoprotein(a) as a marker of cardiovascular health risk in children and adolescents","volume":"11","author":"Genovesi","year":"2023","journal-title":"Biomedicines"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100945_bib0036","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.5551\/jat.14621","article-title":"Guidelines for the management of familial hypercholesterolemia","volume":"19","author":"Harada-Shiba","year":"2012","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ajpc.2025.100945_bib0037","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.5114\/amsad.2020.97105","article-title":"Risk of cardiovascular disease with lipoprotein(a) in familial hypercholesterolemia: a review","volume":"5","author":"Watanabe","year":"2020","journal-title":"Arch Med Sci Atheroscler Dis"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100945_bib0038","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2213-8587(23)00156-0","article-title":"Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study","volume":"11","author":"de","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0039","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacl.2023.03.010","article-title":"Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study","volume":"17","author":"De Boer","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"19","key":"10.1016\/j.ajpc.2025.100945_bib0040","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia","volume":"63","author":"Alonso","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100945_bib0041","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during Cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0042","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","article-title":"The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients","volume":"256","author":"Jansen","year":"2004","journal-title":"J Intern Med"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100945_bib0043","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1373\/clinchem.2005.055228","article-title":"Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia","volume":"51","author":"Holmes","year":"2005","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0044","doi-asserted-by":"crossref","first-page":"356","DOI":"10.14740\/cr1145","article-title":"Lipoprotein(a) and familial hypercholesterolemia: A short review including the laboratory viewpoint","volume":"11","author":"Hamasaki","year":"2020","journal-title":"Cardiol Res"},{"issue":"10","key":"10.1016\/j.ajpc.2025.100945_bib0045","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029223","article-title":"Lipoprotein(a) genotype influences the clinical diagnosis of familial hypercholesterolemia","volume":"12","author":"Olmastroni","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0046","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023136","article-title":"Assessing the accuracy of estimated lipoprotein(a) cholesterol and lipoprotein(a)-free low-density lipoprotein cholesterol","volume":"11","author":"Zheng","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100945_bib0047","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100945_bib0048","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0049","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100945_bib0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100939","article-title":"E pluribus unum","volume":"3","author":"Patel","year":"2024","journal-title":"JACC Adv"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0052","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1210\/clinem\/dgab734","article-title":"Lipoprotein(a) levels at birth and in early childhood: the COMPARE Study","volume":"107","author":"Strandkj\u00e6r","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2-3","key":"10.1016\/j.ajpc.2025.100945_bib0053","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0021-9150(92)90271-H","article-title":"Lipoprotein(a) at birth, in blacks and whites","volume":"92","author":"Rifai","year":"1992","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0054","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0004563220968473","article-title":"Neely RDG. Lp(a): when and how to measure it","volume":"58","author":"Cegla","year":"2021","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.ajpc.2025.100945_bib0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100945_bib0056","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0057","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/00015385.2022.2031377","article-title":"Value of repeated measurements of lipoprotein (a) to assess cardiovascular risk: a retrospective study","volume":"78","author":"Deconinck","year":"2023","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0058","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study","volume":"355","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.100945_bib0059","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: the copenhagen general population study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.100945_bib0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.maturitas.2022.09.012","article-title":"The effect of menopause on lipoprotein (a) concentrations: A systematic review and meta-analysis","volume":"167","author":"Anagnostis","year":"2023","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100945_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101589","article-title":"Relationship between lipoprotein(a) levels and cardiovascular outcomes in postmenopausal women: A systematic review","volume":"48","author":"Masson","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.07.020","article-title":"Serum lipoprotein(a) levels and insulin resistance have opposite effects on fatty liver disease","volume":"308","author":"Jung","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.100945_bib0063","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.02.026","article-title":"Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor","volume":"299","author":"Konishi","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0064","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.510240602","article-title":"Low lipoprotein (a) levels during acute viral hepatitis","volume":"24","author":"Geiss","year":"1996","journal-title":"Hepatol Baltim Md"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1681\/ASN.V111105","article-title":"Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure","volume":"11","author":"Kronenberg","year":"2000","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.ajpc.2025.100945_bib0066","doi-asserted-by":"crossref","unstructured":"Aggarwal HK, Jain D, R K Yadav ML, Sawhney A. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease - PubMed. Published online July 2010. doi:10.3109\/0886022X.2010.486097.","DOI":"10.3109\/0886022X.2010.486097"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0067","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0971-4065.107189","article-title":"Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysis","volume":"23","author":"Gambhir","year":"2013","journal-title":"Indian J Nephrol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100945_bib0068","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a)in chronic kidney disease: Thematic Review Series: lipoprotein (a): coming of age at last","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"issue":"14","key":"10.1016\/j.ajpc.2025.100945_bib0069","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.293.14.1737","article-title":"Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors","volume":"293","author":"Shlipak","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0070","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.V1051027","article-title":"The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up","volume":"10","author":"Kronenberg","year":"1999","journal-title":"J Am Soc Nephrol JASN"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0071","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1681\/ASN.2004110922","article-title":"High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients","volume":"16","author":"Longenecker","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100945_bib0072","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/01.ATV.14.9.1405","article-title":"Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease","volume":"14","author":"Kronenberg","year":"1994","journal-title":"Arterioscler Thromb J Vasc Biol"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100945_bib0073","first-page":"1901","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study","volume":"31","author":"Kollerits","year":"2016","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100945_bib0074","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.ajpc.2025.100945_bib0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.maturitas.2017.02.009","article-title":"The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis","volume":"99","author":"Anagnostis","year":"2017","journal-title":"Maturitas"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0076","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-022-00711-y","article-title":"Menopausal hormone therapy does not lower lp(a)-associated CHD risk","volume":"19","author":"Fern\u00e1ndez-Ruiz","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0077","doi-asserted-by":"crossref","first-page":"64","DOI":"10.22159\/ajpcr.2018.v11i7.24277","article-title":"Altered lipid profile in hypothyroidism: A biochemical viewpoint","author":"Dv","year":"2018","journal-title":"Asian J Pharm Clin Res"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0078","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5455\/medarh.2021.75.11-15","article-title":"Changes of certain metabolic and cardiovascular markers fructosamine, H-FABP and lipoprotein (a) in patients with hypothyroidism","volume":"75","author":"ANaseer","year":"2021","journal-title":"Med Arch"},{"key":"10.1016\/j.ajpc.2025.100945_bib0079","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.atherosclerosis.2021.11.004","article-title":"Cascade testing for elevated lipoprotein(a) in relatives of probands with familial hypercholesterolaemia and elevated lipoprotein(a)","volume":"349","author":"Chakraborty","year":"2022","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100945_bib0080","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamacardio.2023.3548","article-title":"Concordance of a high lipoprotein(a) concentration among relatives","volume":"8","author":"Reeskamp","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0081","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/eurjpc\/zwab167","article-title":"Finding very high lipoprotein(a): the need for routine assessment","volume":"29","author":"Nurmohamed","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2025.100945_bib0082","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0083","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0084","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"issue":"24","key":"10.1016\/j.ajpc.2025.100945_bib0085","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0086","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0087","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/Cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0088","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0089","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100945_bib0090","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0091","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0092","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpc.2025.100945_bib0093","article-title":"Extreme lipoprotein(a) in clinical practice: A cross sectional study","volume":"16","author":"Zafrir","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"9","key":"10.1016\/j.ajpc.2025.100945_bib0094","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0095","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.100945_bib0096","doi-asserted-by":"crossref","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57(11):1953\u20131975. doi:10.1194\/jlr.R071233.","DOI":"10.1194\/jlr.R071233"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0097","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/joim.12187","article-title":"Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease","volume":"276","author":"Hopewell","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.ajpc.2025.100945_bib0098","series-title":"StatPearls","author":"Farzam","year":"2024"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0099","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.atherosclerosis.2012.09.031","article-title":"In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)","volume":"225","author":"Frischmann","year":"2012","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.ajpc.2025.100945_bib0100","article-title":"Lp(a)-associated oxidized phospholipids in healthy black and white participants in relation to apo(a) size, age, and Family structure","volume":"10","author":"Berglund","year":"2021","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis"},{"issue":"13","key":"10.1016\/j.ajpc.2025.100945_bib0101","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1161\/CIRCULATIONAHA.108.836940","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race, apolipoprotein(a) isoform size and cardiovascular risk factors: results from the Dallas Heart Study","volume":"119","author":"Tsimikas","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cccn.2004.07.023","article-title":"Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation","volume":"350","author":"Emanuele","year":"2004","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ajpc.2025.100945_bib0103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1476-511X-12-31","article-title":"Low-molecular-weight lipoprotein (a) and low relative lymphocyte concentration are significant and independent risk factors for coronary heart disease in patients with type 2 diabetes mellitus: lp(a) phenotype, lymphocyte, and coronary heart disease","volume":"12","author":"Suzuki","year":"2013","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.ajpc.2025.100945_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.843602","article-title":"Low molecular weight apolipoprotein(a) phenotype rather than lipoprotein(a) is associated with coronary atherosclerosis and myocardial infarction","volume":"9","author":"Afanasieva","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"22","key":"10.1016\/j.ajpc.2025.100945_bib0105","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ajpc.2025.100945_bib0106","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.ATV.20.12.2619","article-title":"High levels of lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men","volume":"20","author":"Paultre","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in African Americans and Caucasians: the atherosclerosis risk in communities (ARIC) study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100945_bib0108","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0109","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jacl.2020.06.010","article-title":"Lipoprotein(a) levels and association with myocardial infarction and stroke in a nationally representative cross-sectional US cohort","volume":"14","author":"Brandt","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0110","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/ATVBAHA.118.312267","article-title":"Race-based differences in lipoprotein(a)-associated risk of carotid atherosclerosis: the Multi-Ethnic Study of Atherosclerosis","volume":"39","author":"Steffen","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0111","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0112","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1047-2797(98)00063-5","article-title":"The relationship between lipids\/lipoproteins and atherosclerosis in African Americans and whites: the Atherosclerosis Risk in Communities Study","volume":"9","author":"Sorlie","year":"1999","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0113","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003354","article-title":"Associations of genetically predicted lp(a) (Lipoprotein [a]) levels with cardiovascular traits in individuals of European and African ancestry","author":"Satterfield","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"11","key":"10.1016\/j.ajpc.2025.100945_bib0114","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.025397","article-title":"Lipoprotein(a) and the risk for coronary heart disease and ischemic stroke events among black and white adults with cardiovascular disease","volume":"11","author":"Colantonio","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100945_bib0115","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/ATVBAHA.118.311857","article-title":"Lipoprotein(a) and risk of ischemic stroke in the REGARDS study","volume":"39","author":"Arora","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0116","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/ATVBAHA.115.306683","article-title":"Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in Caucasian and black individuals: the Multi-Ethnic Study of Atherosclerosis","volume":"36","author":"Cao","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.ajpc.2025.100945_bib0117","first-page":"343","article-title":"Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America","volume":"48","author":"Enas","year":"1996","journal-title":"Indian Heart J"},{"issue":"6684","key":"10.1016\/j.ajpc.2025.100945_bib0118","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/bmj.298.6684.1345","article-title":"First myocardial infarctions in Asian and white men","volume":"298","author":"Hughes","year":"1989","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0119","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0167-5273(89)90013-2","article-title":"A study of lipid levels in Indian patients with coronary arterial disease","volume":"24","author":"Krishnaswami","year":"1989","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0120","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ihj.2019.04.007","article-title":"Lipoprotein(a): an underrecognized genetic risk factor for malignant coronary artery disease in young Indians","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ajpc.2025.100945_bib0121","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.atherosclerosis.2021.11.018","article-title":"Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population","volume":"349","author":"Loh","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ajpc.2025.100945_bib0122","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2020.09.010","article-title":"Lipoprotein (a) and aortic valve calcium in South Asians compared to other race\/ethnic groups","volume":"313","author":"Makshood","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0123","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.amjcard.2018.12.013","article-title":"Evaluating the potential association between lipoprotein(a) and atherosclerosis (from the Mediators of Atherosclerosis Among South Asians Living in America Cohort)","volume":"123","author":"Huffman","year":"2019","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2025.100945_bib0124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ajhg.2014.11.010","article-title":"The genetic ancestry of African Americans, Latinos, and European Americans across the United States","volume":"96","author":"Bryc","year":"2015","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1016\/j.ajpc.2025.100945_bib0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0126","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0127","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ajpc.2025.100945_bib0128","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/eurjpc\/zwab052","article-title":"Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview","volume":"29","author":"Parthymos","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.ajpc.2025.100945_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.04.134","article-title":"Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation","author":"Schumann","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"20","key":"10.1016\/j.ajpc.2025.100945_bib0130","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.ajpc.2025.100945_bib0131","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"issue":"6","key":"10.1016\/j.ajpc.2025.100945_bib0132","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2025.100945_bib0133","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: the EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ajpc.2025.100945_bib0134","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ajpc.2025.100945_bib0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.ajpc.2025.100945_bib0136","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1093\/eurheartj\/ehac436","article-title":"Lipoprotein(a) and aortic valve stenosis: work in progress","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.ajpc.2025.100945_bib0137","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ajpc.2025.100945_bib0138","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.ajpc.2025.100945_bib0139","first-page":"349","article-title":"Genetics of the lp system","volume":"13","author":"Berg","year":"1963","journal-title":"Acta Genet Stat Med"},{"issue":"44","key":"10.1016\/j.ajpc.2025.100945_bib0140","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667725000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:03:51Z","timestamp":1762639431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667725000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":140,"alternative-id":["S2666667725000182"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.100945","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2025.100945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100945"}}